MDx Sales Drive 42 Percent Increase in Q3 Revenues for Myriad Genetics | GenomeWeb

NEW YORK (GenomeWeb News) – Myriad Genetics reported after the close of the market on Monday that its third-quarter revenues increased 42 percent, driven by a sharp uptick in molecular diagnostics sales.

The Salt Lake City-based firm generated revenues of $87.5 million for the three-month period ended Mar. 31, compared to $61.8 million for the first quarter of 2008. Its molecular diagnostics sales were $86.5 million, up from $59 million in Q1 2008, while its research and other revenue fell to just under $1 million from $2.7 million the year before.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.